WeightWatchers braces for Oprah’s primetime GLP-1 special; Pfizer CEO Albert Bourla’s pay fell 35% to $21.6 million; Insurers meeting with federal officials about Change Healthcare outage.
Five things for pharma marketers to know for Friday morning
FDA rules on Madrigal Pharmaceuticals’ NASH therapy; Wegovy’s label expansion to heart disease may spur Medicare to expand coverage; Vice President Kamala Harris visits abortion clinic.
Five things for pharma marketers to know for Thursday morning
Pfizer reports promising findings in late-stage blood cancer trial; Merck announces a deal with Pearl Bio that could top $1 billion; Allegra launches GPS for clean-air pathways at South by Southwest.
Five things for pharma marketers to know for Thursday morning
Eli Lilly’s Mounjaro has limited availability through February; Samsung Biologics says its net profit fell 21.4% in Q4 2023 due largely to a one-off factor; The FDA denies approval for a newer formulation of tesamorelin that Theratechnologies proposed.
Five things for pharma marketers to know for Monday morning
Will Bernie Sanders subpoena Big Pharma execs?; Drugmakers raise the list prices for Ozempic and Mounjaro; Scientists identify a persistent change in a handful of blood proteins in people with long COVID.
Five things for pharma marketers to know on Tuesday morning
Novartis in talks to buy Cytokinetics; Boston Scientific acquires medtech company Axonics in $3.7 billion deal; Lilly’s Zepbound obesity drug reaches 25,000 new prescriptions mark.
Five things for pharma marketers to know on Tuesday